Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluVax3: Longitudinal Analysis of Influenza Vaccines in Older Adults
NCT05518500Phase 4Active, not recruiting
- Sponsor
- The Jackson Laboratory
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of influenza vaccine in influenza, sponsored by The Jackson Laboratory. Primary endpoint: Change in Antibody Responses to Influenza Vaccine (Years 1-4) at Day 180. Started Aug 2022; status: active, not recruiting.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05518500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518500.